Replies to post #7705 on Repros Therapeutics Inc (RPRX)

[hptaxis]

RPRX RECEIVES DELISTING NOTICE!!! NO REALLY! LOL

[No amount of time will allow this company to survive. But, as typical of Porky, PR after PR will be Pumped out to prolong the shareholder agony, dupe unknowing and ignorant fools, and line Porky's Pockets until the bitter end. The delisting news is even more appropriate on the day that NBIX announces the Elagolix news. Elagoix is safe and effective, entering phase 3, partnered, good for UF, excellent R&D, FDA cooperation, etc. Any fool/idiot who invest in this company deserves all the punishment and misery coming to them. Another Porky Podolski's Pathetic Piss Poor Pitiful Putrefying PR Pump BS.]

Repros to Appeal NASDAQ Delisting Notice
http://finance.yahoo.com/news/Repros-to-Appeal-NASDAQ-bw-988876685.html?x=0&.v=1

Press Release Source: Repros Therapeutics Inc.
On Wednesday June 16, 2010, 1:00 pm

THE WOODLANDS, Texas--(BUSINESS WIRE)--On June 15, 2010, Repros Therapeutics Inc. (NasdaqGM: RPRX - News) received notification from NASDAQ that it has not regained compliance with NASDAQ Listing Rule 5550(a)(2) and, unless the Company appeals NASDAQ’s decision, trading of the Company’s common stock will be suspended and the Company’s securities will be delisted from the NASDAQ Stock Market.

The notification indicates that, historically, NASDAQ appeals panels have generally viewed a reverse stock split as the only definitive plan to resolve a price bid deficiency. [Duh!!! The R/S has always been a no-brainer. After the R/S, the share price will fall below $1 quickly and delisting will occur. In the meantime, Porky's Pockets will be lined.] The notice states that applicable rules have been recently modified, however, to permit the appeals panel to grant additional time, up to 180 calendar days from the date of the notice, if the panel deemed it appropriate, based upon the Company’s plan for compliance and the relevant events that it believes will enable it to regain compliance with the minimum bid price requirement, so long as there is a commitment to effect a reverse stock split if necessary.

Repros intends to promptly submit its plan to NASDAQ supporting its appeal for additional time to regain compliance. The Company’s Board of Directors and its management [This means Porky, nobody else!] is appealing the NASDAQ ruling in order to allow adequate time for the FDA to respond to the Company’s pending submissions for its Androxal drug candidate [Another bunch of CRAP.]. The Company believes that a positive FDA response for its Androxal hypogonadism program will result in an increase in the market cap of the Company and hence its share price. [ROTFLMFAOPIMP] There can be no assurance that the FDA will give a positive response or that NASDAQ will grant Repros sufficient time for the FDA to finish its deliberations. [Dream on, Porky. A twenty year rip off is about to come to an end. Hop on board, Penny Pumpers, this POS is all yours.]

[chloebware]

Do you realize that if Proellex works in these smaller dose trials it will be THE ONLY oral drug of its kind? Now that is woth a couple of hundred shares just to play the lotto. Lighten up a little. You need a beer!

[hptaxis]

The story has NOT changed, RPRX IS a SCAM. AND NBIX cleaned RPRX's clock! Take Note: Androxal is a FAIL.

Neurocrine Biosciences, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares
http://www.marketwatch.com/story/neurocrine-biosciences-inc-announces-exercise-in-full-of-underwriters-option-to-purchase-additional-shares-2012-01-30

SAN DIEGO, Jan. 30, 2012 /PRNewswire via COMTEX/ -- Neurocrine Biosciences, Inc. NBIX +3.58% today announced the closing of the sale of 1,425,000 shares of its common stock pursuant to the exercise in full of an option to purchase such shares granted to the underwriters of Neurocrine's previously announced public offering of common stock that priced on January 19, 2012. Including the additional shares purchased, the offering totaled 10,925,000 shares at a public offering price of $8.10 per share, resulting in gross proceeds of approximately $88.5 million to Neurocrine, before deducting underwriting discounts and commissions and other offering expenses.

[jmkobers: http://www.investorvillage.com/smbd.asp?mb=6869&mn=243&pt=msg&mid=6944549 - NBIX <$3.50 ROTFLMAO]